August 2024

First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLCIvonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC HONG KONG, Aug. 11, 2024 /PRNewswire/ — Akeso, Inc

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: